Tiotropium Bromide Crystalline Solvates for Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing forms of tiotropium bromide for inhalation treatment of respiratory disorders lack sufficient structural stability and uniform particle size, leading to suboptimal delivery and efficacy due to issues like moisture absorption and polymorphic structure changes, which affect physical and chemical stability.
Innovation Solution
Development of new crystalline solvates such as allyl alcohol, furfuryl alcohol, and 1,4-butandiol solvates of tiotropium bromide, prepared using specific solvent systems and processes that enhance thermal and mechanical stability, and characterized using NMR, X-ray powder diffraction, and DSC analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing crystalline forms of tiotropium bromide are used for inhalation, then the drug can be delivered to the target area, but the physical and chemical stability is insufficient due to moisture absorption and polymorphic structure changes
Solution Approach 1:
The patent applies parameter changes by discovering and utilizing different polymorphic forms (Form I, Form II, Form III) and solvate forms of tiotropium bromide, each with distinct crystal structures and stability characteristics. These different crystalline forms exhibit varying degrees of stability against moisture absorption and polymorphic transitions, allowing selection of the most stable form for inhalation therapy
Solution Approach 2:
The patent employs composite material strategies by formulating tiotropium bromide in combination with specific carriers and excipients that enhance stability. The drug is delivered as a dry powder mixture containing tiotropium bromide in defined particle size ranges (0.5-5 μm) combined with carrier materials, creating a composite formulation that maintains structural integrity and stability during storage and inhalation delivery
2Speed
If the particle size is reduced to meet inhalation requirements (1-10μm), then the drug reaches the target area effectively, but the structural stability and uniformity of particle size distribution become difficult to maintain
Solution Approach 1:
The patent applies preliminary action by pre-establishing the optimal particle size distribution range (0.5-5 μm for tiotropium bromide particles) before formulation and delivery. The manufacturing process is designed to produce particles within this specified range from the outset, ensuring both effective inhalation delivery and structural stability. This preliminary definition of particle size parameters guides the entire formulation and processing approach
Solution Approach 2:
The patent utilizes parameter changes by optimizing particle size as a critical parameter for inhalation performance. By controlling particle size within the 0.5-5 μm range and maintaining a narrow distribution, the formulation achieves optimal balance between delivery efficiency and stability. The particle size parameter is carefully adjusted and maintained throughout formulation development and manufacturing
3Object-generated harmful factors
If lower doses are used via inhalation route, then side effects are reduced, but the structural stability and consistent delivery of the active ingredient become more critical
Solution Approach 1:
The patent applies mechanics substitution by replacing less stable crystalline forms with more stable polymorphic forms and solvates of tiotropium bromide. This substitution of the crystalline structure provides enhanced stability that ensures consistent delivery of the active ingredient at low doses, maintaining therapeutic efficacy while minimizing side effects through reliable and predictable drug delivery
Solution Approach 2:
The patent employs parameter changes by optimizing the crystalline form parameters of tiotropium bromide to achieve enhanced stability. By selecting specific polymorphic forms and solvates with proven stability characteristics, the formulation ensures consistent delivery of low doses, maintaining the balance between reduced side effects and reliable therapeutic effect
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new solvates exhibit improved thermal stability and minimized degradation, ensuring effective delivery and enhanced bioavailability by maintaining the crystalline form, thus addressing the limitations of previous forms in meeting inhalation requirements.
Implementation Method 1
new crystalline forms of tiotropium bromide
Implementation Method 2
improved thermal stability and minimized degradation
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Present invention relates to novel crystalline solvates of the active ingredient, preparation processes of said forms, pharmaceutical compositions containing these forms, and the use of said compositions for the treatment of respiratory disorders.